Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary
embolism, is an important cause of preventable mortality and morbidity. In this study, we …

Background International guidelines have endorsed the use of edoxaban or rivaroxaban as
an alternative to low-molecular-weight heparin (LMWH) for the treatment of acute venous …

Abstract Background Venous (VTEs) and arterial thromboembolic events (ATEs) are causes
of morbidity, disability, mortality, and increase in treatment costs in cancer patients. The risk …

Importance Thromboprophylaxis for individuals receiving systemic anticancer therapies has
proven to be effective. Potential to maximize benefits relies on improved risk-directed …

Lung cancer continues to be a difficult disease frequently diagnosed in late stages with a
high mortality and symptom burden. In part because of frequent lung comorbidity, even lung …

Background Venous thromboembolism (VTE) complicates several anticancer regimens
including chemotherapy and antiangiogenic agents. Cyclin‐dependent kinase inhibitors …

Abstract Background The Cancer-VTE Registry evaluates the occurrence and management
of venous thromboembolism in Japanese participants with major solid tumors. Using …

Cancer and coronavirus disease 2019 (COVID-19) have unusual similarities: they both
result in a markedly elevated risk of thrombosis, exceptionally high D-dimer levels, and the …

Cancer-associated venous thrombosis (VTE) increases mortality and morbidity. However,
limited tools are available to identify high risk patients. Upon activation, neutrophils release …